Molecular Partners (MOLN) Q2 2026 earnings summary

Executive summary

• Advanced clinical-stage biotech focused on DARPin therapeutics for targeted cancer therapies, with operations in Switzerland and the US.

• Pipeline includes radio- and switch-DARPins, with multiple candidates in clinical and preclinical stages targeting high unmet needs, including DLL3-targeting MP0712 for SCLC and CD70 for kidney cancer.

• Strategic partnerships and collaborations, notably with Orano Med, support up to 10 targeted radiotherapy programs.

• Clare Fisher elected to Board of Directors, bringing over 20 years of healthcare leadership experience and strengthening corporate governance.

• Continued progress in immune cell engager pipeline, including MP0317 in Phase 2 for cholangiocarcinoma and MP0533 in Phase 1/2a for AML.

Financial highlights

• Cash and cash equivalents of CHF 68 million (USD ~84 million) as of June 30, 2026, down from CHF 114.5 million year-over-year.

• Net cash used in operations was CHF 25.0 million for H1 2026, an improvement from CHF 30.2 million in H1 2025.

• Operating loss of CHF 27.0 million for H1 2026, compared to CHF 33.5 million in H1 2025.

• Net result improved to a loss of CHF 26.7 million from CHF 37.2 million year-over-year.

• Total shareholders' equity at CHF 58.5 million as of June 30, 2026.

Outlook and guidance

• Funding expected to support operations into late 2027, excluding potential R&D partnership payments.

• Initial Phase 1 data for MP0712 anticipated before year-end 2026, with comprehensive safety and efficacy data in 2027.

• CD70 program to enter clinic in 2027; MP0726 to start first-in-human imaging in H2 2026.

• Full-year 2026 operating expenses forecasted at CHF 45-55 million, including CHF 6 million in non-cash costs.

• Phase 2 combo study for MP0317 in cholangiocarcinoma ongoing, with data update expected in 2027.